Quanterix SR-Plex crop640Quanterix Corp, Lexington, Mass, is expanding its single molecule array, or Simoa, portfolio to include the new Quanterix SR-Plex benchtop instrument. The SR-Plex will use single molecule measurements to assess previously undetectable proteins, and can significantly reduce sample volume requirements when compared to alternative approaches. The new instrument is designed in a benchtop format that can be easily integrated with existing automation platforms.

The new platform will also be capable of measuring nucleic acids with ultrasensitivity, without utilizing polymerase chain reaction (PCR).

Kevin Hrusovsky, Quanterix.

Kevin Hrusovsky, Quanterix.

“We are delivering platforms at the intersection of the digital health revolution and life science research,” says Kevin Hrusovsky, executive chairman and CEO at Quanterix. “In addition to a smaller instrument footprint, the SR-Plex has been optimized for increased multiplexing capabilities, making it an easy-to-use and economical option for high-sensitivity biomarker analysis, whether proteins or nucleic acids.”

The SR-Plex will be part of a complete solution, including a menu of more than 70 ultrasensitive protein detection assays, as well as a new series of multiplex assays for critical biomarkers, including the first sixplex Simoa assay for quantitative measurement of elusive inflammatory biomarkers in the blood.

“We are particularly excited that the SR-Plex has the potential to lead to advances in the application of circulating biomarkers, especially for cancer detection and treatment,” says Hrusovsky. “Despite recent innovations in genomic and proteomic technologies, there has been little advancement in the development of tests for immunological biomarkers. Simoa’s multiplexing capabilities and digital sensitivity provides, for the first time, the ability to measure economically circulating clinically relevant concentrations of immunological mediators, exosomes, and miRNA in a single benchtop instrument.”

Myriad RBM Inc, Austin, Texas, will begin using the SR-Plex as part of an early-access program. “We’ve previously worked with the HD-1 analyzer and have been consistently impressed with the flexibility of the Simoa technology and the depth that this approach provides,” says Ralph McDade, PhD, president at Myriad. “It allows us to detect biomarkers we couldn’t previously see with other approaches. Now, as a benchtop instrument that offers multiplexing capabilities, we can optimize our in-house laboratory robotics and liquid handlers to gain significant economies of scale, including sample preservation and throughput, which helps with our bottom-line costs.”

Quanterix will initiate an early-access program for the SR-Plex beginning in the fourth quarter of 2017 and expects full availability of the product in the first quarter of 2018. The SR-Plex is for research use only and not for use in diagnostic procedures.

For more information, visit Quanterix.